Chapter 73 Abnormalities of Fat Distribution in HIV Infection Carl Grunfeld, MD, PhD Shortly after the introduction of combination antiretroviral therapy with HIV protease inhibitors (PIs), changes in fat (Table…
Chapter 23 Enfuvirtide J. Michael Kilby, MD Prior to the accelerated FDA approval in 2003 of the membrane fusion inhibitor, enfuvirtide (ENF), all available antiretroviral agents were directed against one…
Chapter 30 General Immune-Based Therapies in the Management of HIV-Infected Patients Irini Sereti, MD, Joseph A. Kovacs, MD The development of highly active antiretroviral drugs, especially protease inhibitors (PIs) or…
Chapter 77 Diseases of the Esophagus, Stomach, and Bowel C. Mel Wilcox, MD The early years of the acquired immunodeficiency syndrome (AIDS) epidemic highlighted the gastrointestinal (GI) tract as a…
Chapter 39 Microsporidiosis Louis M. Weiss, MD, MPH Microsporidia is a nontaxonomic designation used to refer to a group of obligate, intracellular parasites belonging to the phylum Microsporidia.1,2 The Microsporidia…
Chapter 41 Mycobacterium Avium Complex and Other Atypical Mycobacterial Infections Constance A. Benson, MD, Judith S. Currier, MD CLINICAL SYNDROMES Mycobacterium avium complex (MAC) disease in patients with human immunodeficiency…
Chapter 55 Hepatitis C Infection Mark S. Sulkowski, MD Human immunodeficiency virus (HIV)-infected persons have an increased incidence of hepatitis C and an accelerated course of chronic liver disease, leading…
Chapter 6 Didanosine Raphael Dolin, MD STRUCTURE Didanosine (2′,3′-dideoxyinosine, ddI, Videx, Videx EC) is a nucleoside analog active against human immunodeficiency virus type 1 (HIV-1), HIV-2, simian immunodeficiency virus, and…
Chapter 76 Adrenal, Gonadal, and Thyroid Disorders Joan C. Lo, MD, Morris Schambelan, MD A variety of endocrine disorders have been reported in association with human immunodeficiency virus (HIV) infection…
